American Century Companies Inc. bought a new position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 112,774 shares of the medical research company’s stock, valued at approximately $7,356,000. American Century Companies Inc. owned approximately 0.18% of PRA Health Sciences at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Fuller & Thaler Asset Management Inc. bought a new stake in PRA Health Sciences during the third quarter valued at approximately $124,000. Pacer Advisors Inc. bought a new stake in PRA Health Sciences during the third quarter valued at approximately $152,000. Pacad Investment Ltd. raised its stake in PRA Health Sciences by 22.7% in the fourth quarter. Pacad Investment Ltd. now owns 2,700 shares of the medical research company’s stock valued at $149,000 after buying an additional 500 shares in the last quarter. First Bank & Trust raised its position in shares of PRA Health Sciences by 1.7% in the first quarter. First Bank & Trust now owns 3,159 shares of the medical research company’s stock worth $206,000 after buying an additional 54 shares during the period. Finally, Eqis Capital Management Inc. acquired a new position in shares of PRA Health Sciences during the first quarter worth about $258,000.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences, Inc. (NASDAQ PRAH) traded up 0.65% during trading on Friday, hitting $72.64. The stock had a trading volume of 553,936 shares. PRA Health Sciences, Inc. has a one year low of $39.25 and a one year high of $75.43. The firm has a market cap of $4.54 billion, a price-to-earnings ratio of 43.39 and a beta of 0.48. The stock’s 50-day moving average is $70.17 and its 200 day moving average is $61.75.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Tuesday, April 25th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.58 by $0.02. PRA Health Sciences had a return on equity of 21.87% and a net margin of 5.85%. The business had revenue of $427.08 million during the quarter, compared to analyst estimates of $426.81 million. During the same period last year, the company earned $0.55 earnings per share. PRA Health Sciences’s quarterly revenue was up 14.7% compared to the same quarter last year. Equities analysts anticipate that PRA Health Sciences, Inc. will post $3.14 earnings per share for the current year.

WARNING: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/06/16/american-century-companies-inc-invests-7-356-million-in-pra-health-sciences-inc-prah-updated-updated.html.

A number of research analysts have recently issued reports on PRAH shares. Jefferies Group LLC reiterated a “buy” rating and set a $66.00 target price on shares of PRA Health Sciences in a research report on Thursday, February 23rd. Avondale Partners upgraded PRA Health Sciences from an “underperform” rating to a “market perform” rating and set a $63.00 target price on the stock in a research report on Monday, February 27th. Zacks Investment Research lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, March 2nd. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $76.00 price objective (up from $69.00) on shares of PRA Health Sciences in a research note on Tuesday, June 6th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $65.00.

In other PRA Health Sciences news, insider David W. Dockhorn sold 85,182 shares of the firm’s stock in a transaction dated Monday, March 27th. The stock was sold at an average price of $62.00, for a total transaction of $5,281,284.00. Following the transaction, the insider now directly owns 55,574 shares in the company, valued at $3,445,588. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Colin Shannon sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, March 28th. The shares were sold at an average price of $64.00, for a total value of $3,200,000.00. Following the transaction, the chief executive officer now owns 50,000 shares in the company, valued at $3,200,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 331,575 shares of company stock worth $20,969,915. Corporate insiders own 2.10% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.